A severe psychiatric disorder, MDD causes a great economic burden worldwide. The total costs for depression in the United States amounted to US$83.1 billion in 2000. 1 The total costs of depression in Taiwan in 1994 were US$1.4 billion. 2 MDD accounted for about 14.2 million DALYs in China and 22.7 million DALYs for all other Asia-Pacific countries in 2000. 2 The World Health Organization has predicted that MDD will be second only to ischemic heart disease as a leading cause of disability. 3 Several studies have focused on the prevalence and incidence of MDD. However, prevalence and incidence rates vary greatly. [4] [5] [6] [7] [8] There are several challenges for assessing MDD. First, the course of MDD is episodic and fluctuating, so long-term follow-up is required to observe whether it shifts to a manic state, especially with regard to a differential diagnosis of MDD or bipolar disorder. Second, variability of study instruments and designs can lead to different results. [9] [10] [11] Lifetime prevalence rates for MDD vary widely across countries, ranging from 1.14% to 19.0%. 4, 8, 12, 13 The 1-year prevalence rate ranges from 0.8% to 7.1%. 4, 8, [14] [15] [16] The 1-month prevalence rate was found to be 2.6% to 2.7%. 14, 16 In a US Medicaid HMO, the 1-year prevalence rate of depression was 14.6%. 17 There are a few studies about the incidence of MDD. The annual incidence of MDD has been found to range from 0.3% to 7.5%, with a corresponding pooled rate of 2.9%. 3, [5] [6] [7] Only 30% to 50% of people with MDD use health services for depression. 4, 18, 19 The proportion of patients with depressive disorders who receive antidepressant pharmacotherapy at the primary care facilities ranges from 0% to 38%. 20 Some studies report that the incidence of MDD has been associated with age of onset, sex, ethnicity, SES, or urbanicity. 11, [21] [22] [23] [24] [25] In Taiwan, the single large-sample community survey for MDD found the lifetime prevalence rate to be 1.14%-a much lower rate than rates in Western countries. 8, 12 In March 1995, Taiwan implemented an NHI program offering a comprehensive, unified, and universal health insurance program to all citizens. The coverage provides outpatient service; inpatient care; Chinese medicine; dental care; childbirth, physical therapy, and preventive health care; home care; and rehabilitation for chronic mental illness. The BNHI has contracted with 91% medical institutions in Taiwan, and as many as 96% of the people in Taiwan have joined the NHI program since 1996.
Several epidemiologic methods for evaluating MDD are available, including field surveys to identify all cases and case register studies to evaluate the prevalence and incidence of treated MDD. Although the field survey is the most comprehensive method for epidemiologic study, MDD has a fluctuating course and needs long-term follow-up. In fact, there is no incidence study of MDD in Taiwan. Thus we used a health care registration file to analyze the epidemiologic data on MDD.
In this study, we first present the prevalence and incidence of treated MDD in Taiwan, according to NHI data from 1996 to 2003. Second, we discuss factors associated with the prevalence and incidence of treated MDD. We offer evidencedbased data on MDD for resource evaluation and future policy-making.
Methods

Sample
Access to the NHI medical claims database, including ambulatory care, hospital inpatient care, dental services, and prescription drugs, was provided by the NHRI. The NHRI provided a database of 200 432 randomly selected subjects (about 1% of the population) for application of related health service studies. The data contained ambulatory care and inpatient records and the registration files of the insured. There were no statistically significant differences in age, sex, and costs between the sample group and all enrollees. In our study, 187 583 enrollees were entered in the NHI program on January 1, 1996. Of these, we excluded 8610 foreigners and 42 928 subjects who were younger than age 15 years on December 31, 1995. Our final study sample comprised 136 045 subjects.
Definition of MDD
We identified study subjects who had at least one service claim (for either ambulatory or inpatient care) with a principal diagnosis of MDD according to ICD-9-CM diagnostic criteria 296.2, 296.3, or 296.9 26 according to the diagnosis of catastrophic illness registration, inpatient diagnosis (by frequency), ambulatory diagnosis (by frequency), whether the subject had been diagnosed by a psychiatrist, or whether the subject had used antidepressants. 27, 28 In Taiwan, patients with several kinds of chronic major psychiatric disorders, including ICD-9-CM codes 290 and 293 to 297, can apply for catastrophic illness registration cards given by the BNHI. Individuals with catastrophic illness registration for psychiatric disorders do not need to make copayments when they seek mental health care, although they must still make copayments for nonmental health services. Although there were no absolute rules for the diagnostic algorithm of MDD in claims data, we considered severity, duration, frequency of treatment, psychiatric clinical visiting, and antidepressant use to be priorities for a judgment of MDD in this study.
The Treated Prevalence
Study subjects who had at least one service claim with a principal diagnosis of MDD for either ambulatory or inpatient care and who followed the diagnostic algorithm were defined as the prevalent cases from 1996 to 2003. The cumulative treated prevalence from 1996 to 2003 was calculated. The numerator was the number of prevalent cases of MDD from 1996 to 2003. The denominator was the number of total study subjects in 1996. We also calculated 1-and 8-year (1996 to 2003) sex-and age-specific treated prevalence.
The Treated Incidence Rate
The study subjects who were defined as having MDD during the year but had not been defined as having MDD during the previous year were defined as incident cases. We calculated the treated incidence rate of each year from 1997 to 2003. The numerator was the number of incident cases of MDD in each year. The denominator was the person-year that was contributed by the study subjects. Study subjects who were alive at the end of the year contributed 1 person-year to the denominator. Study subjects who died during the year contributed one-half person-year to the denominator. 29 We also calculated the treated incidence rate by age and sex from 1997 to 2003.
Measurements
We obtained demographic data, including age, sex, ethnicity, insurance amount, region, and urbanicity, from the BNHI insured files. There were 6 age categories: 15 to 24 years, 25 to 34 years, 35 to 44 years, 45 to 54 years, 55 to 64 years, and 65 years or older. Data on ethnicity included Aborigines and non-Aborigines. There were 4 insurance categories: fixed premium, lower than US$640 (TWD 20 000), US$640 to $1280 (TWD 20 000 to 39 999), and US$1281 (TWD 40 000) or more. With NHI, the premiums of the most insured are determined on the basis of the insured wage and premium rate. Insured wage is the insurance amount. The insured amount of the insured is divided into 38 grades ranging from TWD 15 840 to TWD 87 600. For the insured group without salaried income, the average premium remained at TWD 1007. 27 The study subjects were classified according to geographical distribution into 4 regions: northern, central, southern, and eastern. Urbanicity was divided into urban, suburban, and rural categories.
Statistical Analysis
We used the chi-square test to examine the differences in treated 1-year (1996) and cumulative (1996 to 2003) prevalence and the treated incidence rate between sexes in every age group. Multiple logistic regression was used to analyze the associated factors for the prevalent cases of MDD during 1996. Cox regression analysis was used to analyze the predictive factors for occurrence of MDD from 1997 to 2003. We used SAS Version 8.1 (SAS Publishing, 1999) to link and analyze the data. In this study, we set the significance level at 0.05. Table 1 shows the characteristics of the study sample, including age, sex, ethnicity, insurance amount, region, and urbanicity. Figure 1 illustrates the increasing trend in the cumulative prevalence of treated MDD and the annual incidence rate of treated MDD. 
Results
Discussion
Our study is the first to use NHI data to detect the treated MDD prevalence and incidence in Taiwan; no previous studies have discussed the incidence of MDD in Taiwan. Moreover, we observed a fixed cohort for 8 years to analyze the study sample from 1996 to 2003. Since most residents of Taiwan (96%) joined the NHI program, we believe that the treated prevalence and incidence presented here indicate the true proportion of treatment for individuals with MDD in Taiwan.
Our results revealed a cumulative treated prevalence (1996 to 2003) of 17.24 per 1000, which represents a higher rate than that found in a community study during the 1980s in Taiwan (lifetime prevalence, 11.4 per 1000) 12 but a lower rate than was found in the same cross-national study performed in the other countries (lifetime prevalence, 29 to 190 per 1000). 8 Actually, the prevalence of MDD found in the previous community study in Taiwan is much lower than in Western countries. Reasonable explanations include greater availability of consistent social supports, the low rate of broken families in Chinese culture, low comorbidity rates, and older age of MDD onset. 12 Depressive syndromes may manifest differently in Chinese culture, such that the neurasthenia, somatization, or more somatic syndromes may explain part of the difference. 30 Some reports also mention methodological issues in cross-cultural studies, including the standardized diagnostic interview, manifestation of symptoms, interviewer bias, and interviewee bias; it is therefore important to find standardized diagnostic entities to apply to different cultures. 31 Nevertheless, a limitation remains in that the low prevalence of treated MDD in Taiwan needs to be fully clarified.
However, the treated prevalence in our NHI study was higher than that found in the previous community study in Taiwan. We should consider several factors. First, different sampling methods and different diagnostic criteria probably contributed to the differences. Second, social stigma can lead to a denial of symptoms or underreporting of previous depressive episodes, which contributed to underestimating MDD in the previous 1980s community survey, compared with the other countries. 32 Third, and by contrast, individuals with MDD had a better understanding of mental health and sought treatment during the period 1996 to 2003. Fourth, there were many social changes, including industrialization, during the past 20 years, which resulted in more prevalent cases of MDD. Generally, only 30% to 50% of individuals with MDD sought treatment. 4, 18, 19 Thus we look forward to future community epidemiologic studies for further comparison.
The lifetime prevalence of MDD for Chinese Americans in Los Angeles was 6.9%. 33 This rate is lower than rates in Western countries but much higher than rates among Chinese living in China 34 and Taiwanese living in Taiwan. 12 Asia) express their problems in behavioral or somatic terms rather than in emotional ones. 8, 33 The annual treated incidence rate was found to be 1.89 per 1000 per year in 1997, increasing to 2.58 per 1000 per year in 2003, compared with previous studies that reported an annual MDD incidence rate of 2.9%. 3, [5] [6] [7] We found the treated incidence rate of MDD to be lower in the NHI study than in community studies. We propose that, because Taiwan implemented the NHI program in 1995, individuals with MDD first sought treatment during the initial years. Many people with MDD still do not seek treatment.
With respect to age-and sex-specific rates of treated MDD prevalence and incidence, we found that men and women aged 45 years or older had higher treated MDD prevalence and incidence rates. According to previous studies, the mean age of MDD onset is in the mid 20s to mid 30s. 8, 21 Some studies reported 2 peaks for the development of MDD: in the age ranges 15 to 24 years and 45 to 50 years. 11, 16 Among subjects aged 45 years or older in our NHI study, the peak treated incidence rate was found in older individuals, compared with those in community studies, which indicates that individuals with MDD come into contact with services several years after the disorder's onset. Perhaps stigmatization also hindered treatment seeking among individuals with MDD. Moreover, we must consider another peak development of MDD in the group aged 45 to 50 years.
According to the regression results, the treated prevalence rate was highest in the group aged 45 to 64 years and the treated incidence rate was also highest in the group aged 45 to 64 years. This indicates that most patients with MDD sought treatment during late adulthood, and therefore, we must emphasize the need for early detection and treatment for patients with MDD. Despite the wide variations in lifetime prevalence estimates of MDD across countries and studies, the roughly 2-to-1 sex ratio is consistent across cultures. 21, 22, [35] [36] [37] Our study revealed similar findings: female subjects had a higher prevalence of treated MDD-about twice has high as that for male subjects, even in the analyses of age-and sex-specific distribution.
In the United States, Hispanics and whites are at higher risk for MDD than are African Americans and Mexican Americans. 11, 23 Our study revealed no significant difference between Aborigines and non-Aborigines in the prevalence and incidence of treated MDD in Taiwan. Aborigines constitute 2% of the Taiwanese population; however, they represent only 1.4% of the insured people in the NHI program. The question of ethnic difference in regard to MDD should be further investigated.
Although several studies show that individuals with lower SES are at high risk for MDD, 11, 23 no consistent association between SES and MDD incidence has been found among different studies. 24 Our findings showed that MDD is more incident in individuals with the lowest and highest SES. We believe that individuals with the lowest SES experience more stress, which results in a higher incidence of MDD. Individuals with a higher SES are also at risk for MDD-or a higher percentage seek treatment-hypotheses that deserve further observation and study. Findings indicating regional differences may represent differences in resource allocation and equity of psychiatric services. We found no significant difference among regions in the prevalence and incidence of treated MDD. Therefore, similar access exists for the treatment of patients with MDD in different regions in Taiwan, even in the eastern region with the least industrialization.
There are no consistent findings that individuals in rural or urban areas have a lower prevalence of MDD. 25, 38, 39 Our study showed a higher incidence of treated MDD in urban areas. This may indicate that people who live in urban areas either suffer from greater change and stress or have better access to treatment.
In this study, we used longitudinal insurance data to detect the incidence rate of treated MDD, as well as the risk factors. To prevent selection bias, we also used a population-based, randomly selected sample. Some limitations, such as the reliability and validity of the secondary data and the differentiation of MDD from bipolar disorder and minor depression, as well as comorbidity, primary or secondary diagnoses, and over-and underdiagnoses, must be considered. Our study did not include the diagnosis of depressive disorder, not elsewhere classified (ICD-9-CM 311). In Taiwan, the traditional term "neurasthenia" may be classified as ICD-9-CM 311 (depressive disorder, not elsewhere classified) or ICD-9-CM 300.4 (neurotic depression). We need to consider differentiating MDD from minor depression (such as depressive disorder, not elsewhere classified; ICD-9-CM 311) and neurotic depression (ICD-9-CM 300.4). Reliability varies among diagnoses of psychiatric disorders and is highest for the diagnosis of psychosis. The diagnostic accuracy for MDD is lower than that for schizophrenia. We used a diagnostic algorithm to examine the accuracy of MDD diagnosis in our NHI study. A chart review study might further validate our diagnostic algorithm. We should perform the chart review study for further validation of the diagnostic algorithm in future study. Apart from the limitation of using NHI claims data, this study did not discuss such risk factors as education, occupation, and marital status.
Conclusions
The prevalence and incidence rate of treated MDD in Taiwan were both lower than the rates in community studies in Western countries. As the trends of treated prevalence and incidence indicate, treatment for individuals with MDD in Taiwan gradually increased from 1996 to 2003. However, individuals with MDD are still underdiagnosed and undertreated in Taiwan. Consequently, the public health department should further emphasize prevention and treatment of MDD.
Résumé : La prévalence et l'incidence du trouble dépressif majeur traité chez les participants à l'assurance-santé nationale de Taiwan, de 1996 à 2003
Objectif : Nous avons utilisé la base de données de l'assurance-santé nationale (ASN) pour examiner la prévalence et l'incidence du trouble dépressif majeur (TDM) traité et les facteurs associés.
Méthode : L'institut national de recherche en santé a fourni une base de données de 200 432 sujets sélectionnés au hasard pour l'étude. Nous avons obtenu un échantillon aléatoire en population générale, âgé de 15 ans ou plus (n = 136 045) comme cohorte fixe, de 1996 à 2003. Nous avons identifié les sujets de l'étude qui avaient un diagnostic principal de TDM et qui avaient recouru aux services au moins une fois durant ces années, soit pour des soins ambulatoires, soit pour être hospitalisés. 
Résultats
